Dr. Somaiah on Next Steps for CMB305 in Soft Tissue Sarcoma
Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps following the phase I findings of the CMB305 trial in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.
Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps following the phase I findings of the CMB305 trial in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.
The initial next step is to determine the patient population who will benefit the most from this regimen, explains Somaiah.
This drug can be compared against other regimens in the maintenance or third-line setting in order to determine if CMB305 will help a patient delay progression, states Somaiah.
